Skip to main content
Premium Trial:

Request an Annual Quote

Richard Eglen, Michael Woehler, Shelly Gunn

Premium
PerkinElmer announced Richard Eglen has been hired as vice president and general manager of discovery and research reagents for the company’s Life & Analytical unit. Eglen started at his new position on July 10.
 
He was previously the CSO and executive vice president at DiscoveRx. Prior to that, he held executive positions within the pharmaceutical, diagnostic, and biotech industries.

Magellan Biosciences announced the appointment of Michael Woehler to the company’s board of directors. Woehler had been at Parexel from 2001 until February, most recently as an executive vice president.

Shelly Gunn has joined CombiMatrix as its medical director. Gunn received her PhD in genetics from the University of Texas Health Science Center at San Antonio Graduate School of Biomedical Sciences where she focused on the detection of cryptic chromosomal abnormalities in pediatric patients with normal cytogenetics and central nervous system dysmyelination.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.